LIPO LIPELLA PHARMACEUTICALS INC.

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit

PITTSBURGH, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals, Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on addressing serious diseases with significant unmet needs, today announced that CEO Jonathan Kaufman, PhD will be presenting at the 2024 Maxim Healthcare Virtual Summit that is being held on October 15 -17, 2024.

Event: Lipella Presentation - 2024 Maxim Healthcare Virtual Summit

Date: Thursday, October 17th, 2024

Time: 10:30am

Webcast:

Jonathan Kaufman will be available for one-on-one meetings with registered investors of the conference.

About Lipella Pharmaceuticals

Lipella is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Additionally, Lipella maintains a therapeutic focus on diseases with significant, unaddressed morbidity and mortality where no approved drug therapy currently exists. Lipella completed its initial public offering in December 2022. For more information, please visit  or 

CONTACT

Jeff Ramson

PCG Advisory



646-863-6893



EN
09/10/2024

Underlying

LIPOLIPELLA PHARMACEUTICALS INC.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LIPELLA PHARMACEUTICALS INC.

 PRESS RELEASE
Free
LIPO LIPELLA PHARMAC...

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Fol...

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company’s recent delisting from the Nasdaq Capital Market, as well as insight into Lipella’s clinical p...

June 25, 2025 1 EN
 PRESS RELEASE
Free
LIPO LIPELLA PHARMAC...

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company’s common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq’s determination that certain private placement transactio...

June 20, 2025 1 EN
 PRESS RELEASE
Free
LIPO LIPELLA PHARMAC...

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic ...

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled “Systems and Methods of Detecting Interstitial Cystitis.” The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential...

June 17, 2025 1 EN
 PRESS RELEASE
Free
LIPO LIPELLA PHARMAC...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement...

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development Supports late-stage development and scalable manufacturing for LP-310, a non-steroidal oral rinse therapy for Oral Lichen Planus, a condition with no approved treatments PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collab...

June 4, 2025 1 EN
 PRESS RELEASE
Free
LIPO LIPELLA PHARMAC...

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Li...

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “we,” “our,” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two...

May 15, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch